# Trypanocidal Activity of Quinonemethide Triterpenoids from Cheiloclinium cognatum (Hippocrateaceae)

Luciano M. Lião<sup>a,\*</sup>, Gilmar A. Silva<sup>a</sup>, Marcos R. Monteiro<sup>b</sup>, and Sérgio Albuquerque<sup>c</sup>

- <sup>a</sup> Instituto de Química, Universidade Federal de Goiás, Campus Samambaia, C. P. 131, 74001-970 Goiânia, GO, Brazil. Fax: +556235211167. E-mail: luciano@quimica.ufg.br
- b Centro de Caracterização e Desenvolvimento de Materiais, Universidade Federal de São Carlos, C. P. 676, 13565-905 São Carlos, SP, Brazil
- c Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, FCFRP, Universidade de São Paulo, 14040-903 Ribeirão Preto, SP, Brazil
- \* Author for correspondence and reprint requests
- Z. Naturforsch. 63c, 207-210 (2008); received July 27/September 25, 2007

We report the trypanocidal activity of quinonemethide triterpenoids isolated from root extracts of *Cheiloclinium cognatum*, a plant of the Hippocrateaceae family, collected in the Cerrado Reserve at Universidade Federal de Goiás, Brazil. The trypanocidal activity assays showed an effect on the blood trypomastigote forms of the Y strain of *Trypanosoma cruzi* where tingenone and tingenol demonstrated activity on the parasite. Their structures were elucidated on the basis of spectral data, particularly COSY, HMQC and HMBC experiments, and chemical transformations.

Key words: Celastroloids, Trypanosoma cruzi, Hippocrateaceae

#### Introduction

Chagas disease continues being one of the largest public health problems in Latin America. In spite of presenting a significant reduction of new cases the transmission of infection by blood transfusion has become the most important mechanism of transmission (Chiari *et al.*, 1991). Search for new, more effective and less toxic compounds than actually used is necessary due to the low effectiveness of the existent drugs for the therapeutics of the disease. For blood transfusion the only trypanocidal substance currently used to prevent infection is gentian violet, but its use is limited due to its toxic effects and the alarming colour communicated to the skin and urine of transfusion recipients (Sepulveda-Boza and Cassels, 1996).

Our interest for the chemical constituents of Brazilian Cerrado region plants, and particularly for those with biological activity, led us to isolate quinonemethide triterpenoids, known as celastroloids, from the Hippocrateaceae family (Lião, 1997; Jeller *et al.*, 2004). These compounds constitute a relatively small group of natural products encountered exclusively in plants of the Celastraceae and Hippocrateaceae families (Gunatilaka, 1996; Brüning and Wagner, 1978), and have been of interest due to their antitumour, antileukemic, antimicro-

bial (Brüning and Wagner, 1978), antimalarial (Pavanand *et al.*, 1989), and trypanocidal activities (Goijman *et al.*, 1984).

In this paper, we describe the trypanocidal activity of the quinonemethide triterpenoids tingenol (1) and tingenone (2), isolated from the root barks of *Cheiloclinium cognatum* (Miers) A. C. Sm., a tree used in folk medicine to treat fever and oedema. Tingenol was first isolated from *Peritassa campestris* (Lião, 1997; Rodrigues-Filho *et al.*, 2002), but its NMR data was not published. The known quinonemethide triterpenoids 22-hydroxytingenone, 20-hydroxy-20-*epi*-tingenone, celastrol, pristimerin (Gunatilaka, 1996), netzahualcoyondiol (González *et al.*, 1987) and netzahualcoyone (González *et al.*, 1983), were also isolated.

## **Results and Discussion**

Tingenol (1) was isolated as an orange solid with an absorption in the UV-Vis region at 426.4 nm. Its mass spectrum showed the molecular ion peak at m/z 422, suggesting the molecular formula,  $C_{28}H_{38}O_3$ . The <sup>1</sup>H NMR spectrum displayed pattern signals at  $\delta$  6.51 (d, J = 1.2 Hz, H-1),  $\delta$  6.99 (dd, J = 1.2 and 7.2 Hz, H-6),  $\delta$  6.34 (d, J = 7.2 Hz, H-7) and  $\delta$  6.96 (brs, OH-3), characteristic of the A and B rings of quinonemethide triterpenoids.

Fig. 1. Structure of tingenol (1) and tingenone (2).

The data obtained from <sup>1</sup>H NMR spectra are very closely related to those described for the known tingenone (2), except for the signals observed for  $\alpha$ -carbonyl protons (H-22 $\alpha$ , $\beta$  and H-20); they were shifted in comparison to those in tingenone. The shift observed for these protons was caused by the substitution of the carbonyl C-21 atom of 2 by a hydroxy group. The carbinolic proton (H-21) was observed at  $\delta$  3.85 (*brd*, J = 2.4 Hz). A similar situation was found in the <sup>13</sup>C NMR spectrum where the C=O group ( $\delta$  213.7) of **2** was replaced by a secondary carbinolic carbon atom in 1  $(\delta 71.2)$ , confirmed by DEPT experiments. The coupling between the carbinolic proton with H-20, H-22 $\alpha$  and H-22 $\beta$  confirmed the position of the hydroxy group at C-21. The assignment of the stereochemistry of OH-21 $\beta$  was proposed from the coupling constants between H-21 and the vicinal protons (J = 2.4 Hz) requiring all protons to be equatorial according to the dihedral angle. Reduction of the carbonyl group of 2 with NaBH<sub>4</sub> afforded tingenol (1), supporting the structural proposal. All the evidence shown above led to the structure of an alcohol for this compound, namely tingenol (Fig. 1), very closely related to tingenone (2).

Tingenone was evaluated by Goijman and coworkers (1984), under epimastigote forms of parasite (Tulahuén strain), and presented an effective activity at a concentration of 30  $\mu$ M (IC<sub>50</sub> = 10  $\mu$ M).

In the present study, we observed that tingenol and tingenone had a lower activity under trypomastigote forms, the infective form of the parasite. The results obtained showed significant activity of these substances up to  $200 \,\mu\text{g/ml}$ . Table I summarizes the results obtained from the *in vitro* bioassay against trypomastigote forms of *T. cruzi*.

The IC<sub>50</sub> values obtained for tingenol and tingenone are 306.9  $\mu$ m and 486.6  $\mu$ m, respectively, when evaluated under trypomastigote forms. This is simply explained by the variation on susceptibility, that occurs between different strains, and by different parasite forms evaluated in this work, the ones which present variation on the susceptibility to drugs. This fact can be explained by the difference between the composition of the plasmatic membrane of the epimastigote and trypomastigote forms. The first presents a larger percentage of sterols in its composition, mainly ergosterol, which plays an important role in the substances' transport through the plasmatic membrane of the parasite (Da Silveira et al., 1979), turning the epimastigote form more susceptible to the action of exogenous substances.

These results suggest that tingenol and tingenone may be potential compounds for control and treatment of Chagas disease, where new derivatives should be obtained by chemical structure alteration in order to improve the activity on the parasite.

Compound	Inhibition (%)			
	100 μg/ml	200 μg/ml	500 μg/ml	1000 μg/ml
Tingenone (2) Tingenol (1)		53.3 ± 3.1 75.2 ± 4.9	80.2 ± 4.9 85.9 ± 4.3	97.1 ± 1.9 93.8 ± 2.1

Table I. Results from tingenol and tingenone against trypomastigote form of *T. cruzi*.

### **Experimental**

## General experimental procedures

NMR: Bruker DRX 400, in CDCl<sub>3</sub> and TMS as internal standard. EIMS: low resolution on a VG Platform II (Fisons Instruments, Altrincham, England) instrument. IR: Bomem FTIR MB-102 spectrometer (ABB Bomem Inc., Quebec, Canada) in KBr pellets.  $[\alpha]_D$ : Perkin Elmer 241 instrument.

### Plant material

The root barks of *Cheiloclinium cognatum* (Hippocrateaceae) were collected at Universidade Federal de Goiás, Goiânia, GO, Brazil, in June 2000 and identified by Dr. Júlio Antônio Lombardi (Departamento de Botânica do Instituto de Ciêncicas Biológicas, Universidade Federal de Minas Gerais, Brazil). The voucher specimen (19797) is deposited at Herbarium of Instituto de Ciências Biológicas, UFG, Goiânia, GO, Brazil.

#### Extraction and isolation

The root barks of C. cognatum were dried in a circulating air stove and ground. The powder was extracted with CH<sub>2</sub>Cl<sub>2</sub> by maceration for 3 weeks at room temperature. Solvent was removed by distillation under reduced pressure affording a dichloromethanic extract (3.0 g). The dichloromethanic extract was chromatographed on a silica gel column with hexane containing increasing amounts of acetone to yield quinonemethide triterpenoids in mixture and other terpenoids. Separation of the quinonemethide fractions by CC over silica gel, eluting with hexane/CH<sub>2</sub>Cl<sub>2</sub>/MeOH (78:19:3 v/v) and hexane/diethyl ether (70:30 v/v), gave tingenol (1; 50 mg), tingenone (2; 500 mg), 22-hydroxytingenone (35 mg), 20-hydroxy-20-epitingenone (22 mg), celastrol (5 mg), pristimerin (10 mg), netzahualcoyondiol (65 mg) and netzahualcoyone (8 mg).

Tingenol [1(10),3,5,7-tetraen-3,21-dihydroxy-D: A-friedo-24,30-dinoroleanan-2-one-(20 $\beta$ ,21 $\beta$ )] (1): Intense orange crystals, [ $\alpha$ ]<sub>2</sub><sup>5</sup> -43.0° (c 0.56, CHCl<sub>3</sub>). – UV (CHCl<sub>3</sub>):  $\lambda$ <sub>max</sub> (log  $\varepsilon$ ) = 253.6 (4.00), 426.4 (4.12) nm. – IR (KBr):  $\nu$ <sub>max</sub> = 3380, 1709, 1594, 1513 cm<sup>-1</sup>. – <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  = 0.76 (3H, s, CH<sub>3</sub>-27), 0.89 (3H, d, J = 6.8 Hz, CH<sub>3</sub>-30), 1.26 (3H, s, CH<sub>3</sub>-26), 1.27 (3H, s, CH<sub>3</sub>-28), 1.36 (1H, brd, J = 14.0 Hz, H-22 $\beta$ ), 1.45 (3H, s, CH<sub>3</sub>-25), 1.76 (1H, m, H-20), 1.90 (1H, td, J = 12.0 and 5.6 Hz, H-19 $\beta$ ), 2.00 (1H, td, J = 15.2

and 3.6 Hz, H-22 $\alpha$ ), 2.15 (1H, m, H-19 $\alpha$ ), 2.19 (3H, s, CH<sub>3</sub>-23), 3.85 (1H, brd, J = 2.4 Hz, H-21), 6.34 (1H, d, J = 7.2 Hz, H-7), 6.51 (1H, d, J = 1.2 Hz, H-1), 6.96 (1H, brs, OH-3), 6.99 (1H, dd, J = 7.2 and 1.2 Hz, H-6). – <sup>13</sup>C NMR (CDCl<sub>3</sub>, 100 MHz):  $\delta$  = 10.4 (C-23), 18.6 (C-30), 21.4 (C-27), 21.8 (C-26), 25.0 (C-19), 28.9 (C-15), 30.2 (C-12), 30.6 (C-17), 31.4 (C-20), 34.0 (C-11), 35.4 (C-28), 37.4 (C-16), 38.9 (C-25), 40.7 (C-13), 43.2 (C-9), 44.3 (C-18), 44.4 (C-22), 45.2 (C-14), 71.2 (C-21), 117.4 (C-4), 118.3 (C-7), 119.8 (C-1), 127.8 (C-5), 134.1 (C-6), 146.3 (C-3), 165.1 (C-10), 170.3 (C-8), 178.6 (C-2). – EIMS: m/z = 422 (22) [M]<sup>+</sup>, 241 (36), 202 (100), 201 (71), 95 (45), 84 (56) and 81 (28).

## Biological assay

All assays were carried out using blood of mice experimentally infected with the Y strain (Nussenzweig *et al.*, 1953) of *T. cruzi*. This strain is deposited in the Parasitology Laboratory of Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Brazil.

Trypomastigote forms were collected by cardiac puncture of Swiss albino mice in the parasitemy peak (7th day) after infection with the Y strain of T. cruzi. The blood was diluted with non-infected murine blood to give a concentration of ca.  $2 \cdot 10^6$ trypomastigote forms/ml. Stock solutions of the compounds to be tested were prepared by dissolution in DMSO (dimethyl sulfoxide). The bioassays were performed in triplicate on microtitre plates (96 wells). For each sample, aliquots of the stock solutions were added to the diluted blood in such quantities as to give final concentrations of 100, 200, 500 and  $1000 \,\mu\text{g/ml}$  of mixture in the wells. The plates were incubated at 4 °C during 24 h, and the number of parasites was determined according to Brener (1962). As controls blood of infected mice without any addition (negative control), infected blood containing DMSO in equivalent amounts as the samples, and infected blood containing gentian violet (positive control) at  $250 \,\mu\text{g}$ ml were used.

## Acknowledgement

The authors thank Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), CAPES (Fundação Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) and Fundação de Apoio à Pesquisa da UFG (FUNAPE) for the financial support.

- Brener Z. (1962), Therapeutic activity and criterion of cure on mice experimentally infected with *Trypanosoma cruzi*. Rev. Inst. Med. Trop. São Paulo **4**, 389–396
- Brüning R. and Wagner H. (1978), Übersicht über die Celastraceen-Inhaltsstoffe: Chemie, Chemotaxonomie, Biosynthese, Pharmakologie. Phytochemistry 17, 1821–1858.
- Chiari E., De Oliveira A. B., Raslan D. S., Mesquita A. A., and Tavares K. G. (1991), Screening *in vitro* of natural products against blood forms of *Trypanosoma cruzi*. Trans. R. Soc. Trop. Med. Hyg. **85**, 372–374.
- Da Silveira J. F., Abrahamsohn P. A., and Colli W. (1979), Plasma membrane vesicles isolated from epimastigote forms of *Trypanosoma cruzi*. Biochim. Biophys. Acta 550, 222–232.
- Goijman S. G., Turrens J. F., Marini-Bettolo G. B., and Stoppani A. O. M. (1984), Inhibicion del crecimento y la biosintesis de macromoleculas en *Trypanosoma cruzi* por productos naturales: Efectos de la miconidina y la tingenona. Medicina-Buenos Aires **44**, 361–370.
- González A. G., Fraga B. M., González C. M., Ravelo A. G., Ferro E., Dominguez X. A., Martinez M. A., Fayos J., Perales A., and Rodríguez M. L. (1983), X-Ray analysis of netzahualcoyone, a triterpene quinone from *Orthosphenia mexicana*. Tetrahedron Lett. 24, 3033–3036.
- González A. G., Bazzocchi I. L., Ravelo A. G., Luiz J. G., Dominguez X. A., Vazquez G., and Cano G. (1987), Triterpenos y triterpenoquinonas de *Rzedow*-

- skia tolantoguensis (Celastraceae). Rev. Lat. Am. Quim. 18, 83–87.
- Gunatilaka A. A. L. (1996), Triterpenoid quinonemethides and related compounds (celastroloids). In: Progress in the Chemistry of Organic Natural Products. Springer-Verlag, Wien, Vol. 67, pp. 1–123.
- ducts. Springer-Verlag, Wien, Vol. 67, pp. 1–123. Jeller A. H., Silva D. H. S., Lião L. M., Bolzani V. S., and Furlan M. (2004), Antioxidant phenolic and quinonemethide triterpenes from *Cheiloclinium cognatum*. Phytochemistry **65**, 1977–1982.
- Lião L. M. (1997), Alcalóides sesquiterpênicos piridínicos e triterpenos quinonametídeos degradados de *S. campestris* (Hippocrateaceae). PhD Thesis, Universidade Federal de São Carlos, Brazil.
- Nussenzweig V., Sonntag R., Biancalana A., Freitas J. L. P., Nussenzweig R. S., and Kloetzel J. (1953), Ação de corantes trifenilmetânicos sobre o *Trypanosoma cruzi in vitro*. Emprego da violeta-de-genciana na profilaxia da transmissão da moléstia de chagas por transfusão de sangue. Hospital **44**, 731–744.
- Pavanand K., Webster H. K., Yongvanitchit K., Kun-Anake A., Dechatiwongse T., Nutakul W., and Bansiddhi J. (1989), Schizontocidal activity of *Celastrus paniculatus* Willd. against *Plasmodium falciparum in vitro*. Phytother. Res. **3**, 136–139.
- Rodrigues-Filho E., Barros F. A. P., Fernandes J. B., and Braz-Filho R. (2002), Detection and identification of quinonemethide triterpenes in *Peritassa campestris* by mass spectrometry. Rapid Commun. Mass Spectrom. **16**, 627–633.
- Sepulveda-Boza S. and Cassels B. K. (1996), Plant metabolites active against *Trypanosoma cruzi*. Planta Med. **62**, 98–105.